Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Therapeutic potential of COX-2 inhibitors in arthritis
Autore:
Jackson, CG;
Indirizzi:
Univ Utah, Sch Med, Dept Internal Med, Div Rheumatol, Salt Lake City, UT 84132 USA Univ Utah Salt Lake City UT USA 84132 matol, Salt Lake City, UT 84132 USA
Titolo Testata:
EXPERT OPINION ON INVESTIGATIONAL DRUGS
fascicolo: 7, volume: 10, anno: 2001,
pagine: 1317 - 1325
SICI:
1354-3784(200107)10:7<1317:TPOCII>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RANDOMIZED CONTROLLED TRIAL; ENDOPEROXIDE-H SYNTHASE-1; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; GASTROINTESTINAL TOXICITY; SELECTIVE-INHIBITION; CYCLOOXYGENASE-2 INHIBITOR; SYNOVIAL TISSUES; LONG-TERM;
Keywords:
arthritis; cyclooxygenase; COX-1; COX-2; NSAID; prostaglandins;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
63
Recensione:
Indirizzi per estratti:
Indirizzo: Jackson, CG Univ Utah, Sch Med, Dept Internal Med, Div Rheumatol, 50 N MedDr, Salt Lake City, UT 84132 USA Univ Utah 50 N Med Dr Salt Lake City UT USA 84132 UT 84132 USA
Citazione:
C.G. Jackson, "Therapeutic potential of COX-2 inhibitors in arthritis", EXPERT OP I, 10(7), 2001, pp. 1317-1325

Abstract

Arthritis and related musculoskeletal conditions occur with great frequency in the population world wide, causing significant morbidity and, in some instances, increased mortality. Affecting both the young and the old, 15% of the population in the US was estimated in 1995 to have some form of arthritis with an increase to 18% projected by the year 2020 ([1]). The economicimpact of arthritis and related disorders in the US alone was estimated tobe US $194.4 billion in 1992 and future costs are virtually certain to increase given the chronic nature of these diseases, their expanding prevalence and the considerable expense associated with newer therapies ([2]). With no cure presently available, the aim of current treatment is to reduce inflammation, ameliorate symptoms and improve functional capacity. Non-steroidal antiinflammatory drugs (NSAIDs), which suppress the formation of pro-inflammatory prostaglandins by antagonising the action of cyclooxygenase (COX),have been the mainstay of arthritis treatment for hundreds, if not, thousands of years. The clinical use of NSAIDs, however, has long been associatedwith significant toxicity. The recognition of two COX isoforms, cyclooxygenase-l (COX-1) and cyclooxygenase-2 (COX-2), both suppressed by traditionalNSAIDs, has led to an expanded hypothesis of NSAID action which consists of two postulates, namely, the efficacy of NSAIDs in the treatment of arthritis is due to the suppression of COX-2, while much of the toxicity associated with non-selective NSAIDs is the consequence of COX-1 suppression. The emergence of agents which selectively inhibit COX-2 has made it possible to clinically evaluate the validity of each of these postulates. In this report, the published experience with selective COX-2 inhibitors in the treatment of mechanical and inflammatory arthropathies is reviewed to examine the premise that isolated COX-2 suppression is comparable in efficacy to the dual COX-1/COX-2 suppression produced by non-selective NSAIDs.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 01:43:52